Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone
Key Highlights
- ➤LP-184 was generally well tolerated in 16 recurrent glioblastoma patients.
- ➤Recommended expansion dose set at 0.39 mg/kg intravenously on days 1 and 8.
- ➤No objective radiographic responses occurred with LP-184 monotherapy in recurrent glioblastoma.
- ➤Spironolactone reduced tumor ERCC3 approximately 80% after three daily doses.
- ➤Combination modeling projects intratumoral LP-184 concentrations 2- to 3-fold above cell-killing levels.
Expert Statements
Reginald Ewesuedo, Vice President of Clinical Development at Lantern Pharma
“Glioblastoma is especially difficult to treat because a therapy must both reach the brain at effective levels and overcome the tumor's ability to repair the damage.”
Reginald Ewesuedo, Vice President of Clinical Development at Lantern Pharma
“This study shows LP-184 is well tolerated in patients with recurrent GBM and points directly to how we can improve its activity in the tumor.”
Reginald Ewesuedo, Vice President of Clinical Development at Lantern Pharma
“By removing a key DNA repair protein with spironolactone, we aim to make the LP-184 that reaches the tumor considerably more effective.”
Panna Sharma, President and CEO of Lantern Pharma
“Limited brain exposure is why many drugs fail in glioblastoma, and this paper is direct about that challenge and specific about the answer.”
Panna Sharma, President and CEO of Lantern Pharma
“Rather than push the dose higher, we used patient pharmacokinetic data, insights from our RADR® AI platform and our collaborators' models at Johns Hopkins to design a combination that makes the drug reaching the tumor work harder.”
Panna Sharma, President and CEO of Lantern Pharma
“We now have a defined dose and schedule to carry into the planned Phase 1b/2a study with our CNS-focused subsidiary, Starlight Therapeutics.”
Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone
Publication in Cancer Research Communications establishes the recommended dose for expansion and a clinically translatable dosing strategy for the planned Phase 1b/2a trial (NCT07431216)
Get started
Create a free account to read the full story.